Computational analysis of drug transport in tumor microenvironment as a critical compartment for nanotherapeutic pharmacokinetics
暂无分享,去创建一个
Mauro Ferrari | Milos Kojic | Arturas Ziemys | Kenji Yokoi | Miljan Milosevic | M. Ferrari | A. Ziemys | M. Kojic | K. Yokoi | Steve Klemm | Steve Klemm | M. Milošević
[1] R K Jain,et al. Extravascular diffusion in normal and neoplastic tissues. , 1984, Cancer research.
[2] A. Santoro,et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] P. Okunieff,et al. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.
[4] D. Hume,et al. Unravelling mononuclear phagocyte heterogeneity , 2010, Nature Reviews Immunology.
[5] A. Ziemys,et al. The role of payload hydrophobicity in nanotherapeutic pharmacokinetics. , 2014, Journal of pharmaceutical sciences.
[6] Mauro Ferrari,et al. Hierarchical modeling of diffusive transport through nanochannels by coupling molecular dynamics with finite element method , 2011, J. Comput. Phys..
[7] D Guthrie,et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] N. Kojic,et al. Computer Modeling in Bioengineering: Theoretical Background, Examples and Software , 2008 .
[9] Mauro Ferrari,et al. Frontiers in cancer nanomedicine: directing mass transport through biological barriers. , 2010, Trends in biotechnology.
[10] Matthias G Wacker,et al. Nanotherapeutics--product development along the "nanomaterial" discussion. , 2014, Journal of pharmaceutical sciences.
[12] R. Jain,et al. Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.
[13] C. Presant,et al. Tumor‐based pharmacokinetics has greater significance for anticancer drugs than does blood‐based pharmacokinetics , 2004, Clinical pharmacology and therapeutics.
[14] Mark E. Davis,et al. Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.
[15] N. Kojic,et al. Transport in biological systems , 2011 .
[16] C. Presant,et al. Association of intratumoral pharmacokinetics of fluorouracil with clinical response , 1994, The Lancet.
[17] H. Maeda,et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[18] C. Prestidge,et al. Nanoparticle layers controlling drug release from emulsions. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[19] Kinam Park,et al. Facing the truth about nanotechnology in drug delivery. , 2013, ACS nano.
[20] H. Maeda. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.
[21] A Ziemys,et al. A multiscale MD-FE model of diffusion in composite media with internal surface interaction based on numerical homogenization procedure. , 2014, Computer methods in applied mechanics and engineering.
[22] G Cumming,et al. Morphometry of the Human Pulmonary Arterial Tree , 1973, Circulation research.
[23] H. Derendorf,et al. Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Distribution in Tissue , 2004, Antimicrobial Agents and Chemotherapy.
[24] Mauro Ferrari,et al. Capillary-wall collagen as a biophysical marker of nanotherapeutic permeability into the tumor microenvironment. , 2014, Cancer research.